STOCK TITAN

LENSAR, Inc. - LNSR STOCK NEWS

Welcome to our dedicated page for LENSAR news (Ticker: LNSR), a resource for investors and traders seeking the latest updates and insights on LENSAR stock.

LENSAR, Inc. (LNSR) is at the forefront of next-generation femtosecond laser technology, specializing in refractive cataract surgery. The company's flagship product, the LENSAR Laser System, offers unmatched precision and accuracy, optimizing visual outcomes for cataract patients. This cutting-edge system features the proprietary Augmented Reality™, LENSAR’s advanced 3-D imaging, measurement, and guidance technology. By providing high-resolution ocular images in a single scan, the system ensures precise surgical incisions and treatments, all within a single procedure room.

Unlike other femtosecond cataract lasers, the LENSAR Laser System is specifically built for refractive cataract surgery. Designed from the ground up with the needs of cataract surgeons in mind, the system integrates a suite of proprietary technologies aimed at improving visual outcomes, efficiency, and reproducibility. These technologies include Streamline IV and IntelliAxis, which assist surgeons with imaging, procedure planning, and precision.

At its core, LENSAR, Inc. is a commercial-stage medical device company committed to revolutionizing refractive eye surgery. Their product portfolio extends beyond the laser system to include the associated consumable components, such as the disposable patient interface device (PID) kits and procedure licenses necessary for each surgical procedure.

LENSAR's focus on innovation doesn't stop at technology. They are dedicated to building a vibrant team of talented and motivated individuals who share their passion for making a significant impact on patients' lives. The company continues to push the boundaries of what's possible in refractive cataract surgery, ensuring that their technology remains at the cutting edge of medical advancements.

Rhea-AI Summary
LENSAR, Inc. (Nasdaq: LNSR) exceeded its 2023 target of 30 ALLY placements by installing 44 systems, increasing revenue by 18% in Q4 and 19% for the full year 2022. The company aims to expand internationally and maintain growth in the U.S., with a focus on femtosecond laser cataract surgery technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.77%
Tags
-
Rhea-AI Summary
LENSAR, Inc. (Nasdaq: LNSR) announced the grant of stock options to newly-hired non-executive employees, totaling 4,175 shares at an exercise price of $4.70 per share. The options vest over a period of time, subject to continued service, and are part of the 2024 Employment Inducement Incentive Award Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.77%
Tags
none
-
Rhea-AI Summary
LENSAR, Inc. (Nasdaq: LNSR) announced the release of its fourth-quarter and full-year 2023 financial results on March 4, 2024. The company will host a conference call to discuss the financial results and recent corporate highlights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.84%
Tags
conferences earnings
Rhea-AI Summary
LENSAR, Inc. (Nasdaq: LNSR) announced increased ALLY® Adaptive Cataract Treatment System installed base to 39 systems with a backlog of 8 additional systems for installation as of September 30, 2023. Total revenue increased 26% and U.S. procedure volume increased 16% over the third quarter 2022. The strong quarterly growth was driven by 11 ALLY System installs and increased procedure volume, attributed to the significantly increased speed and ergonomic efficiencies of ALLY.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.44%
Tags
-
Rhea-AI Summary
LENSAR, Inc. (Nasdaq: LNSR) will release its third quarter 2023 financial results on November 9, 2023. The company specializes in femtosecond laser solutions for cataract treatment. A conference call and webcast will be held at 8:30 am ET to discuss the results and recent corporate highlights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.12%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.73%
Tags
Rhea-AI Summary
LENSAR, Inc. will release its second quarter 2023 financial results on August 9, 2023. A conference call and webcast will be held to discuss the results and recent corporate highlights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.81%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.51%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.45%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
conferences earnings

FAQ

What is the current stock price of LENSAR (LNSR)?

The current stock price of LENSAR (LNSR) is $7.7 as of December 20, 2024.

What is the market cap of LENSAR (LNSR)?

The market cap of LENSAR (LNSR) is approximately 85.4M.

What does LENSAR, Inc. specialize in?

LENSAR, Inc. specializes in next-generation femtosecond laser technology for refractive cataract surgery.

What is the LENSAR Laser System?

The LENSAR Laser System is a cutting-edge femtosecond laser designed for precise and accurate refractive cataract surgery.

What makes the LENSAR Laser System unique?

It is the only femtosecond cataract laser specifically built for refractive cataract surgery, offering high-resolution 3-D imaging and precise surgical incisions.

What is Augmented Reality™ in the context of LENSAR?

Augmented Reality™ is LENSAR’s advanced 3-D imaging, measurement, and guidance system that provides high-resolution ocular images in a single scan.

What is included in LENSAR's product portfolio?

LENSAR's product portfolio includes the LENSAR Laser System with Streamline IV and IntelliAxis, along with associated consumable components such as PID kits.

What are the consumable components of the LENSAR Laser System?

The consumable components include a disposable patient interface device (PID) kit and a procedure license required for each surgical procedure.

What is the primary focus of LENSAR, Inc.?

LENSAR, Inc. focuses on revolutionizing refractive eye surgery through innovative femtosecond laser technology.

How does LENSAR contribute to the surgical process?

LENSAR's system aids surgeons by providing precise imaging, simplified procedure planning, and high accuracy in surgical incisions.

How does LENSAR ensure the effectiveness of its technology?

LENSAR's technology is built from the ground up with input from cataract surgeons, ensuring it meets their specific needs for precision and efficiency.

What drives the success of LENSAR, Inc.?

LENSAR's success is driven by a dedicated team of talented and motivated individuals passionate about improving patients' lives through advanced medical technology.

LENSAR, Inc.

Nasdaq:LNSR

LNSR Rankings

LNSR Stock Data

85.37M
9.31M
19.57%
42.42%
0.38%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
ORLANDO